SCHEMBL5571244

SCHEMBL5571244

N#CCc1ccc([AsH2])cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
ENPP2 Q13822 1/20 0.36
TNF P01375 1/20 0.36
PKM P14618 2/20 0.35
MMP3 P08254 1/20 0.34
NPC1 O15118 2/20 0.34
LMNA P02545 2/20 0.34
MAPT P10636 2/20 0.34
HTT P42858 1/20 0.34
CYP1A1 P04798 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP1B1 Q16678 1/20 0.33
GAA P10253 1/20 0.33
THRB P10828 1/20 0.32
RAB9A P51151 1/20 0.32
FLT3 P36888 1/20 0.31
ABCB1 P08183 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2154504 0.86 KMT2A (0.47) KMT2AKDM4ETDP1L3MBTL1ENPP2
SCHEMBL31337590 0.79 KMT2A (0.40) KMT2AKDM4ETDP1L3MBTL1ENPP2
SCHEMBL196175 0.78 MMP3 (0.50) KMT2AKDM4ETDP1L3MBTL1ENPP2
SCHEMBL23137321 0.78 MMP3 (0.50) KMT2AKDM4ETDP1L3MBTL1ENPP2
SCHEMBL8763328 0.78 KMT2A (0.42) KMT2AKDM4ETDP1L3MBTL1ENPP2
Bromide SCHEMBL30583553 0.77 KMT2A (0.39) KMT2AKDM4ETDP1L3MBTL1ENPP2
SCHEMBL2939551 0.74 CA1 (0.41) KMT2AKDM4ETDP1L3MBTL1ENPP2
SCHEMBL37742 0.74 IDO1 (0.46) KMT2AKDM4ETDP1L3MBTL1LMNA
SCHEMBL448467 0.74 MMP3 (0.57) KMT2AKDM4EL3MBTL1MMP3NPC1
SCHEMBL249189 0.74 LOXL2 (0.58) MAPTHTTALDH1A1CYP2A6LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250415-B2 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-31 US disclosed
US-20040266761-A1 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and Tetrahydropyrimidinyl-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266761-A1 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and Tetrahydropyrimidinyl-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor Xa inhibitors PEPD, F11, TPSAB1 KMT2A 3292/4885KDM4E 4443/4885TDP1 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.